LLY Quote, Financials, Valuation and Earnings

Biogen has a net margin of 32.59% compared to Eli Lilly and's net margin of 10.87%. Eli Lilly and's return on equity of 80.24% beat Biogen's return on equity of 10.33%.

Eli Lilly and has a consensus price target of $1,008.64, signalling upside risk potential of 14.03%. On the other hand Biogen has an analysts' consensus of $190.50 which suggests that it could grow by 60.3%. Given that Biogen has higher upside potential than Eli Lilly and, analysts believe Biogen is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.509, which suggesting that the stock is 49.093% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.61%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $13.5B, which are larger than Biogen quarterly revenues of $2.5B. Eli Lilly and's net income of $4.4B is higher than Biogen's net income of $266.7M. Notably, Eli Lilly and's price-to-earnings ratio is 75.54x while Biogen's PE ratio is 10.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.75x versus 1.79x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of 32.59% compared to Eli Lilly and's net margin of 19.72%. Eli Lilly and's return on equity of 80.24% beat Gilead Sciences's return on equity of 32.29%.

Eli Lilly and has a consensus price target of $1,008.64, signalling upside risk potential of 14.03%. On the other hand Gilead Sciences has an analysts' consensus of $113.75 which suggests that it could grow by 10.26%. Given that Eli Lilly and has higher upside potential than Gilead Sciences, analysts believe Eli Lilly and is more attractive than Gilead Sciences.

Eli Lilly and has a beta of 0.509, which suggesting that the stock is 49.093% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.61%. Gilead Sciences offers a yield of 3.01% to investors and pays a quarterly dividend of $0.79 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Eli Lilly and quarterly revenues are $13.5B, which are larger than Gilead Sciences quarterly revenues of $6.7B. Eli Lilly and's net income of $4.4B is higher than Gilead Sciences's net income of $1.3B. Notably, Eli Lilly and's price-to-earnings ratio is 75.54x while Gilead Sciences's PE ratio is 21.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.75x versus 4.53x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 32.59% compared to Eli Lilly and's net margin of -117.16%. Eli Lilly and's return on equity of 80.24% beat Moderna's return on equity of -29.09%.

Eli Lilly and has a consensus price target of $1,008.64, signalling upside risk potential of 14.03%. On the other hand Moderna has an analysts' consensus of $49.96 which suggests that it could grow by 83.55%. Given that Moderna has higher upside potential than Eli Lilly and, analysts believe Moderna is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.509, which suggesting that the stock is 49.093% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.61%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $13.5B, which are larger than Moderna quarterly revenues of $956M. Eli Lilly and's net income of $4.4B is higher than Moderna's net income of -$1.1B. Notably, Eli Lilly and's price-to-earnings ratio is 75.54x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.75x versus 3.30x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 32.59% compared to Eli Lilly and's net margin of --. Eli Lilly and's return on equity of 80.24% beat Viking Therapeutics's return on equity of --.

Eli Lilly and has a consensus price target of $1,008.64, signalling upside risk potential of 14.03%. On the other hand Viking Therapeutics has an analysts' consensus of $89.50 which suggests that it could grow by 258.14%. Given that Viking Therapeutics has higher upside potential than Eli Lilly and, analysts believe Viking Therapeutics is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.509, which suggesting that the stock is 49.093% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.838, suggesting its less volatile than the S&P 500 by 16.205%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.61%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $13.5B, which are larger than Viking Therapeutics quarterly revenues of --. Eli Lilly and's net income of $4.4B is higher than Viking Therapeutics's net income of -$45.6M. Notably, Eli Lilly and's price-to-earnings ratio is 75.54x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.75x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.